Denifanstat

®

MedChemExpress

| Cat. No.: | HY-112829 |
|--------------------|---|
| CAS No.: | 1399177-37-7 |
| Molecular Formula: | C ₂₇ H ₂₉ N ₅ O |
| Molecular Weight: | 439.55 |
| Target: | Fatty Acid Synthase (FASN) |
| Pathway: | Metabolic Enzyme/Protease |
| Storage: | 4°C, protect from light * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light) |

SOLVENT & SOLUBILITY

| In Vitro | DMSO : 100 mg/mL (227.51 mM; Need ultrasonic) | | | | | | |
|----------|--|---|-----------|------------|------------|--|--|
| Pro | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | | |
| | | 1 mM | 2.2751 mL | 11.3753 mL | 22.7505 mL | | |
| | | 5 mM | 0.4550 mL | 2.2751 mL | 4.5501 mL | | |
| | | 10 mM | 0.2275 mL | 1.1375 mL | 2.2751 mL | | |
| | Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution | | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution | | | | | | |
| | 3. Add each solvent o Solubility: ≥ 2.5 mg | one by one: 10% DMSO >> 90% cor g/mL (5.69 mM); Clear solution | n oil | | | | |

| BIOLOGICAL ACTIVITY | | | | |
|---------------------------|---|--|--|--|
| | | | | |
| Description | Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC ₅₀ of 0.052 μM and an EC ₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research ^{[1][2]} . | | | |
| IC ₅₀ & Target | IC50: 0.052 μM (FASN) ^[1] | | | |
| In Vitro | Denifanstat (compound 152) is a potent FASN inhibitor ^[2] . ?Fatty Acid Synthase (FASN) inhibition prevents palmitoylation of SARS-CoV2 spike protein ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | |

Product Data Sheet

N-NH

[⊚]N

CUSTOMER VALIDATION

• Nat Metab. 2021 Sep 27;1-10.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Johan D., et al. Heterocyclic modulators of lipid synthesis. WO2012122391A1.

[2]. Minhyoung Lee, et al. Fatty Acid Synthase inhibition prevents palmitoylation of SARS-CoV2 Spike Protein and improves survival of mice infected with murine hepatitis virus. BioRxiv, December 21, 2020.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA